Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Alkeon Capital Management LLC

Alkeon Capital Management LLC reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 42.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,101,000 shares of the company's stock after selling 796,601 shares during the period. Alkeon Capital Management LLC owned 2.72% of Keros Therapeutics worth $17,429,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boxer Capital Management LLC acquired a new position in shares of Keros Therapeutics in the fourth quarter worth $3,958,000. Darwin Global Management Ltd. increased its position in Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after purchasing an additional 163,403 shares in the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in Keros Therapeutics by 37.9% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 155,347 shares of the company's stock valued at $2,459,000 after purchasing an additional 42,734 shares during the last quarter. Northern Trust Corp lifted its holdings in Keros Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 296,467 shares of the company's stock valued at $4,693,000 after purchasing an additional 30,111 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Keros Therapeutics by 140.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 40,356 shares of the company's stock worth $639,000 after purchasing an additional 23,550 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KROS shares. Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Truist Financial reduced their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Oppenheimer reduced their target price on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating on the stock in a research report on Thursday, January 16th. Finally, Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $40.33.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 22.90% of the stock is currently owned by corporate insiders.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $14.65 on Friday. The stock has a 50-day simple moving average of $11.92 and a 200-day simple moving average of $26.32. The stock has a market capitalization of $594.95 million, a P/E ratio of -2.81 and a beta of 1.39. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.